KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Assets (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Other Non-Current Assets for 16 consecutive years, with $470000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 710.34% year-over-year to $470000.0, compared with a TTM value of $470000.0 through Sep 2025, up 710.34%, and an annual FY2024 reading of $130000.0, down 62.21% over the prior year.
  • Other Non-Current Assets was $470000.0 for Q3 2025 at TherapeuticsMD, up from $428000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $470000.0 in Q3 2025 and bottomed at $58000.0 in Q2 2024.
  • Average Other Non-Current Assets over 5 years is $240277.8, with a median of $253000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets tumbled 99.54% in 2021, then soared 710.34% in 2025.
  • Year by year, Other Non-Current Assets stood at $253000.0 in 2021, then changed by 0.0% to $253000.0 in 2022, then soared by 35.97% to $344000.0 in 2023, then crashed by 62.21% to $130000.0 in 2024, then soared by 261.54% to $470000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for TXMD at $470000.0 in Q3 2025, $428000.0 in Q2 2025, and $211000.0 in Q1 2025.